BMY BRISTOL MYERS SQUIBB CO
Pharmaceutical Preparations · NYSE · SEC CIK 14272 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.2%
TTM net income YoY53.1%
TTM EPS YoY51.9%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR3.7%
Margins
Gross margin69.2%
Operating margin—
Net margin18.5%
FCF margin18.6%
EBITDA margin—
Returns
ROE44.1%
ROA10.0%
ROIC (approx.)—
Asset turnover0.54x
Leverage & solvency
Liabilities / assets73.6%
Debt / equity1.83x
Current ratio1.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.15x
Accruals ratio-1.5%
Payout ratio55.4%
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13.07B | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B |
| Cost of revenue | $4.15B | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B |
| Gross profit | $8.92B | $9.25B | $8.07B | $8.40B | $8.79B | $8.90B | $8.17B | $7.53B |
| R&D expense | $2.37B | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B |
| SG&A expense | $1.70B | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B |
| Interest expense | $403.00M | $407.00M | $411.00M | $432.00M | $480.00M | $485.00M | $494.00M | $496.00M |
| Pretax income | $2.54B | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175.00M |
| Income tax | $374.00M | $770.00M | $561.00M | $384.00M | $919.00M | $460.00M | $509.00M | $99.00M |
| Net income | $2.16B | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72.00M |
| EPS (basic) | 1.06 | 1.62 | 1.31 | — | 1.08 | 0.64 | 1.21 | — |
| EPS (diluted) | 1.05 | 1.62 | 1.31 | — | 1.08 | 0.64 | 1.20 | — |
| Dividends declared per share | 0.63 | 0.63 | 0.63 | 0.63 | 0.62 | 0.62 | 0.62 | 0.62 |
| Weighted avg. shares (diluted) | 2.05B | 2.05B | 2.05B | — | 2.04B | 2.04B | 2.04B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.57B | $8.72B | $9.57B | $10.21B | $15.73B | $12.61B | $10.88B | $10.35B |
| Short-term investments | $3.01B | $2.35B | $912.00M | $464.00M | $776.00M | $1.00B | $907.00M | $513.00M |
| Receivables | $9.19B | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B |
| Inventory | $2.70B | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B |
| Current assets | $29.77B | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B |
| PP&E, net | $7.97B | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B |
| Goodwill | $21.73B | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B |
| Intangibles | $16.94B | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B |
| Total assets | $88.77B | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B |
| Current liabilities | $18.75B | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B |
| Short-term debt | $1.03B | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B |
| Long-term debt | $41.85B | $42.09B | $42.15B | $42.85B | $44.47B | $44.47B | $46.16B | $47.60B |
| Total debt | $42.88B | $43.12B | $44.46B | $45.11B | $48.98B | $49.19B | $49.71B | $49.65B |
| Total liabilities | $65.37B | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B |
| Shareholders' equity | $23.40B | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B |
| Net debt | $33.30B | $34.40B | $34.89B | $34.90B | $33.25B | $36.57B | $38.84B | $39.30B |
| Cash flow statement | ||||||||
| Operating cash flow | $4.18B | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B |
| Capital expenditure | $344.00M | $305.00M | $347.00M | $370.00M | $320.00M | $361.00M | $260.00M | $378.00M |
| Free cash flow | $3.84B | $3.09B | $757.00M | $1.60B | $5.99B | $3.56B | $1.69B | $4.06B |
| Investing cash flow | -$2.10B | -$1.61B | -$131.00M | -$1.46B | -$1.70B | -$473.00M | -$499.00M | -$196.00M |
| Financing cash flow | -$1.22B | -$2.63B | -$1.56B | -$6.03B | -$1.49B | -$1.84B | -$993.00M | -$1.64B |
| Depreciation & amortization | $151.00M | $139.00M | $594.00M | $977.00M | $159.00M | $165.00M | $1.01B | $1.88B |
| Stock-based compensation | $138.00M | $135.00M | $146.00M | $133.00M | $139.00M | $138.00M | $144.00M | $120.00M |
| Dividends paid | $1.29B | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.